nCoV: Developing CoV-bnMABs for therapy of highly pathogenic coronaviruses including SARS-CoV-2

nCoV：开发 CoV-bnMAB 用于治疗高致病性冠状病毒（包括 SARS-CoV-2）

• 批准号: MC_PC_19060
• 负责人: Xiao-Ning Xu
• 金额: $ 78.29万
• 依托单位: Imperial College London
• 依托单位国家: 英国
• 项目类别: Intramural
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MC_PC_19060
• 关键词: nCoV; Developing; CoV; bnMABs; therapy

Since December 2019 the emergence of severe acute respiratory infections (COVID-19)caused by the new coronavirus SARS-CoV-2 in China has posed a huge threat to globalhealth, with rapid infection of more than 45,000 people and over 1000 deaths by February11, 2020. Currently there is no effective treatment or vaccine available for CoV infectionsin humans, largely due to the diversity of CoV family in wildlife and periodic zoonotictransmission from animal hosts to humans. The aim of this proposal is to develop a groupof ‘universal’ therapeutic antibodies, called coronavirus broadly neutralizing monoclonalantibodies (CoV-bnMABs), capable of treating and protecting against different members ofthe CoV family including the current outbreak of SARS-CoV-2. We intend to bring CoVbnMABsinto clinical trial within a period of 12 months by characterization of theirspecificity to the SARS-CoV-2 as well as protective efficacy and safety in animal models. The outcome of this study would address an immediate unmet medical need and could provide effective tools against emerging pandemic CoV of the future.

自2019年12月以来，中国出现新型冠状病毒SARS-CoV-2引起的严重急性呼吸道感染(新冠肺炎)，对全球健康构成巨大威胁，截至2020年2月11日，快速感染人数超过4.5万人，死亡人数超过1000人。目前尚无针对人类冠状病毒感染的有效治疗方法或疫苗，这主要是由于野生动物中冠状病毒家族的多样性以及动物宿主向人类周期性传播的缘故。这项提议的目的是开发一组被称为冠状病毒广泛中和单克隆抗体(CoV-bnMAbs)的“通用”治疗性抗体，能够治疗和保护不同的CoV家族成员，包括目前爆发的SARS-CoV-2。我们打算在12个月内将CoVbnMAb投入临床试验，通过鉴定它们对SARS-CoV-2的特异性以及在动物模型中的保护效果和安全性。这项研究的结果将解决当前未得到满足的医疗需求，并可能提供有效的工具来应对未来新出现的大流行性冠状病毒。

项目成果

Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms.

• DOI: 10.3390/vaccines11010058
• 发表时间: 2022-12-27
• 期刊: Vaccines
• 影响因子: 7.8
• 作者: Cantoni D;Siracusano G;Mayora-Neto M;Pastori C;Fantoni T;Lytras S;Di Genova C;Hughes J;On Behalf Of The Ambulatorio Medico San Luca Villanuova Group;Lopalco L;Temperton N
• 通讯作者: Temperton N

Production, titration, neutralisation and storage of SARS-CoV-2 lentiviral pseudotypes

SARS-CoV-2慢病毒假型的生产、滴定、中和和储存

• DOI: 10.6084/m9.figshare.13502580
• 发表时间: 2020
• 作者: Genova C

The role of pseudotype neutralization assays in understanding SARS CoV-2.

• DOI: 10.1093/oxfimm/iqab005
• 发表时间: 2021
• 期刊: Oxford open immunology
• 作者: Cantoni D;Mayora-Neto M;Temperton N
• 通讯作者: Temperton N

Production, Titration, Neutralisation, Storage and Lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lentiviral Pseudotypes

• DOI: 10.21769/bioprotoc.4236
• 发表时间: 2021-11-05
• 期刊: BIO-PROTOCOL
• 影响因子: 0.8
• 作者: Di Genova, Cecilia;Sampson, Alex;Temperton, Nigel
• 通讯作者: Temperton, Nigel

The antigenic anatomy of SARS-CoV-2 receptor binding domain.

• DOI: 10.1016/j.cell.2021.02.032
• 发表时间: 2021-04-15
• 期刊: Cell
• 影响因子: 64.5
• 作者: Dejnirattisai W;Zhou D;Ginn HM;Duyvesteyn HME;Supasa P;Case JB;Zhao Y;Walter TS;Mentzer AJ;Liu C;Wang B;Paesen GC;Slon-Campos J;López-Camacho C;Kafai NM;Bailey AL;Chen RE;Ying B;Thompson C;Bolton J;Fyfe A;Gupta S;Tan TK;Gilbert-Jaramillo J;James W;Knight M;Carroll MW;Skelly D;Dold C;Peng Y;Levin R;Dong T;Pollard AJ;Knight JC;Klenerman P;Temperton N;Hall DR;Williams MA;Paterson NG;Bertram FKR;Siebert CA;Clare DK;Howe A;Radecke J;Song Y;Townsend AR;Huang KA;Fry EE;Mongkolsapaya J;Diamond MS;Ren J;Stuart DI;Screaton GR
• 通讯作者: Screaton GR